...Aki Aoyama; Yutaro Yoshitomi; Akihiko Shimomura; Yukino Kawamura; Tomoko Taniyama; Atsumasa Kurozumi; Shuji Kubota; Yukio Hiroi; Chikako Shimizu Introduction: Entrectinib is a multikinase inhibitor used to treat neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced...

... frequently in salivary gland-type tumors, making them a promising therapeutic target in patients with advanced disease. Recent studies have shown that TRK inhibitors, such as entrectinib, larotrectinib and repotrectinib, are effective in treating solid tumors harboring NTRK gene fusions. This underscores...

... is ROS1 G2032R, and some studies have found that even newly developed ROS1 TKIs, such as entrectinib and lorlatinib, show a decreased efficacy against it. The optimal therapies for ROS1-fusion-positive NSCLC and how such cases can be sequenced have not yet been established. Case Presentation: We herein...

... reported; however, it is in-frame and similar to other known oncogenic NTRK fusions. At the time of entrectinib initiation, the patient had clear disease progression on the right leg on standard of care immunotherapy. She was commenced on entrectinib 200 mg once daily for 2 weeks. Dose escalation...

... gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year. Adverse events of rash, dysgeusia, and peripheral edema were observed, and the patient required temporary drug interruption; however, we were able to continue...